Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Irritable bowel syndrome (IBS) is the most common functional GI disorder in which abdominal
pain and/or discomfort is associated with changes in bowel habit, and with features of
disordered defecation. IBS affects 10-20% of the population and causes a marked reduction of
quality of life in affected individuals.The high prevalence of IBS is accompanied by large
societal economic burdens and negative effects on the quality of life in affected patients.
It is divided into 3 types IBS-D diarrhea predominant, IBS-C constipation predominant, IBS-M
mixed sub type.
Phase:
Phase 3
Details
Lead Sponsor:
Next Gen Pharma India Pvt. Ltd.
Collaborator:
Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India